ABBA Therapeutics closed ”Seed B” financing round
Basel, Switzerland – 20.08.2018 – ABBA Therapeutics successfully closed “Seed B” financing round with European investors. The raised fund will be used to accelerate the preclinical efficacy study with cutting-edge animal models and advance two lead candidates for clinical efficacy study.
About ABBA Therapeutics
ABBA Therapeutics is a Swiss biotechnology company founded in Basel in 2016. ABBA Therapeutics focuses on developing next-generation antibody drugs for cancer immunotherapy. The lead project is to develop therapeutic antibodies targeting a novel immune checkpoint family member across both lymphoid and myeloid lineages for a better and broader response of cancer patients to IO therapies.
Further contact: firstname.lastname@example.org; www.abba-therapeutics.com